A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis
NCT ID: NCT07230353
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
47 participants
INTERVENTIONAL
2025-10-21
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
NCT01187563
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
NCT01730456
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
NCT05489224
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
NCT00380744
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
NCT06201416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
XmAb 13676 administered SC
XmAb13676
Biological
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XmAb13676
Biological
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inadequate response to, loss of response to, or intolerance to available RA therapies.
* Stable doses of RA medications prior to screening
* Use of highly effective methods of contraception
Exclusion Criteria
* Recurrent infections or active clinically significant infection
* Active or untreated latent tuberculosis
* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xencor, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Osterman, MD, MS
Role: STUDY_DIRECTOR
Xencor, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arensia Research Clinic
Tbilisi, , Georgia
Xencor Investigative Site
Tbilisi, , Georgia
Arensia Research Clinic
Chisinau, , Moldova
Xencor Investigative Site
Auckland, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XmAb13676-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.